Investors should be aware of three significant challenges confronting Pfizer next year. First, the company is playing catch-up in the high-growth GLP-1 weight-loss drug market, where competitors have already secured leading market share and accelerated patient adoption. Second, Pfizer faces looming patent expirations on its top three blockbusters: Ibrance in 2027, Eliquis in 2028 and Vyndaqel also in 2028, collectively responsible for over $15 billion in annual revenues. Third, with the dividend payout ratio approaching 100%, free cash flow could be strained if revenue growth falters, raising the risk of a dividend cut or halt in payout increases. While Pfizer retains a robust balance sheet and promising late-stage assets, income-focused investors should monitor these headwinds closely.

Pfizer is set to report Q4 results before the market open on February 3. Consensus estimates call for adjusted earnings of $0.57 per share, down from $0.63 in the year-ago quarter, and revenue of $16.83 billion versus $17.76 billion a year earlier, according to Benzinga Pro. On January 20, Pfizer expanded its vaccine capabilities through a licensing agreement with Novavax for the Matrix-M adjuvant, signaling potential upside in its immunization portfolio. Ahead of the release, the firm’s most accurate covering analysts have revised forecasts modestly downward, reflecting pressure from pandemic product declines and ongoing competition in core therapeutic areas.